
ImmunityBio, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
ImmunityBio develops immunotherapy treatments that aim to activate the body's natural killer cells and T cells to fight cancer and infectious diseases. Its lead product, Anktiva, is approved for use alongside BCG therapy in treating certain forms of bladder cancer.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Simon Barry J.Director | Sell | $269K | 25,000at $10.75 | Oct 5, 2026 |
| Cohen CherylDirector | Sell | $851K | 81,056at $10.50 | Oct 2, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable IBRX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.